Hyper Unison
Unison provides an API for data harmonization and federation in personalized medicine. Their solution eliminates the need for local data transformation, allowing users to create SQL queries for patient cohorts according to OMOP and instantly harmonize data from heterogeneous sources. Leveraging an ML algorithm with human-in-the-loop automation, the process is streamlined from months to minutes. This enables users to instantly use harmonized data between biobanks, internal datasets, and proprietary datasets. Unison facilitates the creation of large, decentralized patient cohorts for accurate stratification in drug discovery, diagnostics development, and clinical trials. The platform ensures data protection while enabling federated and synchronous workflows across data for GWAS, ML, and bioinformatics. They also offer a multi-omics data layer, leveraging insights from genomic population-scale datasets to bespoke proteome and RNA studies, scaling capabilities to identify and leverage novel drug targets. Their business model appears to be a SaaS API for data harmonization and federation.
Hyper Unison
Unison provides an API for data harmonization and federation in personalized medicine. Their solution eliminates the need for local data transformation, allowing users to create SQL queries for patient cohorts according to OMOP and instantly harmonize data from heterogeneous sources. Leveraging an ML algorithm with human-in-the-loop automation, the process is streamlined from months to minutes. This enables users to instantly use harmonized data between biobanks, internal datasets, and proprietary datasets. Unison facilitates the creation of large, decentralized patient cohorts for accurate stratification in drug discovery, diagnostics development, and clinical trials. The platform ensures data protection while enabling federated and synchronous workflows across data for GWAS, ML, and bioinformatics. They also offer a multi-omics data layer, leveraging insights from genomic population-scale datasets to bespoke proteome and RNA studies, scaling capabilities to identify and leverage novel drug targets. Their business model appears to be a SaaS API for data harmonization and federation.